4Q Revenues: $3.3 million (+27%)
4Q Loss: $12.5 million (loss of $14.5 million 4Q11)
FY Revenues: $10.7 million (revenues were $20.3 million FY11)
FY Loss: $56.1 million (loss of $47.9 million FY11)
Comments: Growth in the quarter was primarily due to the $1.0 million development milestone under a collaboration with Lilly, partially offset by decreases in revenues from our neglected diseases programs. R&D expenses were down 14% to $12.0 million in the quarter.